MEGIN is delighted to be among the delegates of leading UK innovators heading to California this week (12-16 September 2022) as part of ABHI’s mission to bolster trade partnerships and promote the strengths of UK HealthTech stateside.

The visit builds on the successes of recent trade missions organised by the Association of British HealthTech Industries (ABHI) to Texas and Tennessee as part of its flagship US Accelerator programme.

California – also known as the Golden State – is home to the largest concentration of life sciences organisations in the world and the region is renowned as a primary destination for tech start-ups. The region is famous for housing Silicon Valley, the nation’s most well-known home to major tech companies and incubator for tech startups.

In addition, California is home to over 388 hospitals and a life science ecosystem that generates over $169 billion in revenue. The sector currently employs more than 1.4 million people, making California the number one state for employment in the life sciences and a key state for many HealthTech companies.

ABHI’s week-long programme will provide participants with unprecedented access to key opinion leaders, investor networks and world-class hospital systems across some of its most impactful and valuable life sciences ecosystems, including Los Angeles and San Francisco – known as the birthplace of biotech.

Along with a cohort of over 30 UK companies, MEGIN will be showcasing our leading MEG Technology.

“MEGIN is delighted to be among the UK HealthTech pioneers joining the ABHI trade mission to California. The state is currently home to two MEGIN devices, and we hope to continue expansion in the region. We aim to build greater MEG awareness on this trip, and highlight how our non-invasive technology can support clinical outcomes in epilepsy through data allowing for more informed decision-making, as well as MEG’s utilization in research.
We look forward to meeting with clinical leaders, exploring the opportunities for collaboration within the region’s healthcare and life sciences ecosystem, and showcasing what we have to offer.”

California is known as a life science powerhouse and the region offers companies unparalleled opportunities for collaboration, innovation and discovery. San Francisco – which is home to the largest biotech cluster in the world – boasts world-class research universities and is the home of industry giants such as Genentech Inc.

The life sciences sector in Los Angeles has also experienced exponential growth in the last 5 years and the city is renowned as one of the nation’s top life sciences hub.

The state is deeply committed to actively recruiting, supporting and retaining life sciences companies, with a number of organisations in operation to help businesses navigate its fast-growing innovation ecosystem.

ABHI’s week-long mission will introduce members to the leaders from across this dynamic ecosystem, including hospital systems, accelerators, business chambers and professional service companies. The visit will provide a prime opportunity for members to explore the strengths California boasts in life sciences while fostering partnerships and providing them with advice and guidance to help build and de-risk their market access strategy.

Centred in Texas, the ABHI US Accelerator is delivered in partnership with the Dell Medical School, one of the United States’ most pioneering academic institutions, based at the University of Texas, in Austin. Using the state as a springboard to other key states, the programme offers nationwide support, drawing on the relationships and connections ABHI has cultivated across the US.

Central to the 12-month programme is ABHI’s calendar of trade missions, which take place throughout the year, taking members to key states across the US, enabling them to explore new markets, minimise risk, meet new customers and gain valuable market insight.

The cohort of companies taking part in the visit to California in September will be showcasing a range of UK HealthTech products and solutions. Throughout the week, meetings will take place with senior leadership from hospital systems. The mission will incorporate a series of group meetings, networking events, working groups and introductions to a range of supporting organisations such as Hoag Healthcare, UCLA Health, Children’s Hospital Los Angeles, Cedars-Sinai, BioscienceLA, Stanford Medicine, Irvine Chamber of Commerce, Wilson Sonsini & others.

Throughout the rest of the year, participants of this year’s ABHI US Accelerator will also take part in missions to other key states, taking them as far wide as Minnesota, Florida, and Boston, where this year’s MedTech Conference is being held.

For more information, visit:

About ABHI
ABHI is the UK’s leading industry association for health technology (HealthTech).

ABHI supports the HealthTech community to save and enhance lives. Members, including both multinationals and small and medium sized enterprises (SMEs), supply products from syringes and wound dressings to surgical robots and digitally enhanced technologies. We represent the industry to stakeholders, such as the government, NHS and regulators. HealthTech plays a key role in supporting delivery of healthcare and is a significant contributor to the UK’s economic growth. HealthTech is the largest employer in the broader Life Sciences sector, employing 138,100 people in 4,140 companies, with a combined turnover of £27.6bn. The industry has enjoyed growth of around 5% in recent years. ABHI’s 320 members account for approximately 80% of the sector by value.


MEGIN is a neuroscience technology company based in Helsinki, Finland. The company is focused on developing innovative solutions for functional brain mapping for the presurgical evaluation of epilepsy, brain tumors or other lesions of the brain. For over 30 years, MEGIN has been the global leader in magnetoencephalography (MEG) technology. The TRIUX™ neo provides a non-invasive, real-time view of patient-specific neural activity with millimeter accuracy and millisecond resolution, providing the most precise information currently available on the market.

© 2022 MEGIN – TRIUX™ neo is available for sale in EU and USA markets. In other geographical areas, contact your local MEGIN representative. TRIUX™ neo is intended to non-invasively locate regions of epileptic activity within the brain and, in conjunction with other diagnostic data, in neurosurgical planning. All other applications are research in nature. Please contact for data references and any further information.


Media Contact
[email protected]